このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Artificial Intelligence Enhanced Remote Monitoring in Interstitial Lung Disease (AIRMILD)

2026年9月21日 更新者:King's College London

A Mixed-Methods Feasibility Study Evaluating Artificial Intelligence Enhanced Remote Monitoring in Interstitial Lung Disease

The goal of this clinical trial is to learn whether artificial intelligence AI-enhanced remote monitoring (AIRM) is feasible, safe and acceptable for adults with fibrotic interstitial lung disease (fILD). The artificial intelligence (AI) system uses information collected through home monitoring to identify patterns that may suggest a person's lung condition is getting worse. The AI does not make treatment decisions. Its outputs are reviewed by healthcare professionals.

The main questions this study aims to answer are:

Is AIRM feasible and acceptable for people with fILD and their healthcare professionals? Can it be used safely to help identify possible worsening of fILD? How well does the AI system identify clinical deterioration?

Participants will take part for about 12 months. They will:

Measure their lung function and oxygen levels at home each week using connected monitoring devices.

Report their breathlessness and cough symptoms each week using the patientMpower app.

Complete questionnaires about their health and their experience of remote monitoring at the start of the study and every 3 months.

Continue to receive their usual clinical care.

Some participants will also be invited to an interview or focus group to discuss their experience of AI-enhanced remote monitoring. Healthcare professionals involved in the study may also be invited to discuss their experience of using the system.

The AI system is investigational and is being evaluated as part of this study. Healthcare professionals will review relevant AI-generated alerts before taking any clinical action. The AI will support, rather than replace, clinical judgement.

調査の概要

状態

まだ募集していません

詳細な説明

AIRMILD is a prospective, single-arm, mixed-methods feasibility study evaluating artificial intelligence-enhanced remote monitoring (AIRM) in people with fibrotic interstitial lung disease (fILD). Approximately 120 participants will be recruited from the interstitial lung disease (ILD) service at Guy's and St Thomas' NHS Foundation Trust (GSTT).

The study will evaluate AIRM version 1.0, an investigational artificial intelligence (AI) algorithm integrated within the patientMpower remote monitoring platform. AIRM analyses longitudinal multimodal remote monitoring data, including home spirometry, pulse oximetry, symptom scores and patient-reported measures, to identify patterns associated with potential clinical deterioration.

AIRM is intended to support clinical review rather than replace clinical assessment or clinical decision-making. It will not make autonomous diagnoses or treatment decisions. AIRM-generated outputs that may contribute to clinical management will be reviewed by an appropriately qualified clinician before clinical action is taken. Clinicians will retain independent clinical oversight and responsibility for clinical decisions. Participants will continue to receive usual clinical care throughout the study.

AIRM version 1.0 is investigational and is not UKCA or CE marked. The prediction algorithm will be fixed before prospective evaluation and will not be retrained or modified during participant follow-up. This will allow the performance of the predefined model to be evaluated prospectively against clinically identified deterioration.

The study will assess the feasibility of delivering an AIRM pathway in clinical practice, including participant engagement with remote monitoring and the practical integration of AI-generated information into clinical review. Safety evaluation will include assessment of situations in which AIRM generates an alert without subsequent clinical deterioration and situations in which clinical deterioration occurs without a preceding AIRM alert. The study will also evaluate the performance of AIRM in identifying potential clinical deterioration.

A mixed-methods evaluation will explore the acceptability, usability and perceived clinical value of AIRM. A purposive sample of participants will be invited to take part in qualitative interviews or focus groups following their period of remote monitoring. Healthcare professionals involved in the pathway will also be invited to participate. Qualitative data will be analysed thematically to explore experiences of remote monitoring, interaction with the AI-enhanced pathway, perceived benefits and concerns, and factors that may affect future implementation.

Findings from the quantitative and qualitative components will be considered together to assess the feasibility, safety and acceptability of the pathway and to inform the design of future evaluation of AIRM in fILD.

研究の種類

介入

入学 (推定)

120

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Aged 18 years or older.
  • Diagnosis of fibrotic interstitial lung disease (fILD) confirmed through multidisciplinary team review at a tertiary ILD centre, based on high-resolution computed tomography (HRCT) and standard clinical assessment.
  • Forced vital capacity (FVC) >45% predicted.
  • Able to perform spirometry and use a home spirometer safely and reliably.
  • Availability of baseline pulmonary function tests (PFTs), preferably within the preceding 6 months as part of routine clinical care.
  • Access to a compatible smart device with internet connectivity.
  • Able to understand study procedures, communicate with the research team, and complete study questionnaires and remote monitoring tasks.
  • Has capacity to provide informed consent.

Exclusion Criteria:

  • Previous participation in the REMILD study.
  • Estimated life expectancy of less than 6 months, as judged by the treating clinician.
  • Contraindication to spirometry in accordance with Association for Respiratory Technology and Physiology (ARTP) guidelines.
  • Current or recent acute exacerbation of ILD, confirmed clinically and/or radiologically, within the previous 4 weeks.
  • Active or life-limiting malignancy that, in the opinion of the treating clinician, is likely to affect participation, adherence to study procedures, or interpretation of study outcomes.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:他の
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:AI-enhanced remote monitoring pathway

Participants will receive AI-enhanced remote monitoring (AIRM) for 12 months using the patientMpower platform. Participants will undertake home spirometry and pulse oximetry, report symptoms, and complete patient-reported measures. AIRM version 1.0, an investigational artificial intelligence (AI) algorithm, will analyse longitudinal remote monitoring data to identify patterns associated with potential clinical deterioration. AIRM-generated outputs that may contribute to clinical management will be reviewed by an appropriately qualified clinician before any clinical action is taken. AIRM will support, rather than replace, clinical judgement, and participants will continue to receive usual clinical care.

AI-enhanced remote monitoring (AIRM) delivered through the patientMpower platform for 12 months. Participants will use connected home spirometry and pulse oximetry devices and report symptoms and patient-reported measures. AIRM version 1.0 is an investigational artificial intelligence (AI) algorithm that analyses longitudinal multimodal remote monitoring data to identify patterns associated with potential clinical deterioration in fibrotic interstitial lung disease (fILD). AIRM-generated outputs that may contribute to clinical management will be reviewed by an appropriately qualified clinician before any clinical action is taken. The algorithm will remain fixed during the prospective study and will not be retrained or modified during participant follow-up. AIRM supports, rather than replaces, clinical judgement and usual clinical care.

他の名前:
  • AIRM

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Recruitment Rate of Eligible Participants
時間枠:Up to 24 weeks

Recruitment rate will be calculated as the number of eligible individuals who provide informed consent and enrol in the study divided by the total number of eligible individuals approached for participation, multiplied by 100. The outcome will be reported as a percentage.

Up to 24 weeks
Percentage of Enrolled Participants Retained at 12 Months
時間枠:Up to 12 months

Retention rate will be calculated as the number of enrolled participants who remain enrolled in the study through to the end of the 12-month active remote monitoring period divided by the total number of participants enrolled, multiplied by 100. The outcome will be reported as a percentage.

Up to 12 months
Percentage of Weekly Home Spirometry Measurements Completed
時間枠:Up to 52 weeks

Calculated as the number of scheduled weekly home spirometry measurements completed by participants divided by the total number of scheduled home spirometry measurements, multiplied by 100.

Up to 52 weeks
Percentage of Scheduled Pulse Oximetry Measurements Completed
時間枠:Up to 52 weeks

Calculated as the number of scheduled weekly pulse oximetry measurements completed by participants divided by the total number of scheduled pulse oximetry measurements, multiplied by 100.

Up to 52 weeks
Percentage of Scheduled Weekly Cough Assessments Completed (Cough Visual Analogue Scale)
時間枠:Up to 52 weeks

Calculated as the number of scheduled weekly Cough Visual Analogue Scale assessments completed by participants divided by the total number of scheduled Cough Visual Analogue Scale assessments, multiplied by 100. The Cough Visual Analogue Scale assesses cough severity during the past week on a scale from 0 to 100, with higher scores indicating greater cough severity.

Up to 52 weeks
Percentage of Scheduled Weekly Breathlessness Assessments Completed (Breathlessness Visual Analogue Scale)
時間枠:Up to 52 weeks

Calculated as the number of scheduled weekly Breathlessness Visual Analogue Scale assessments completed by participants divided by the total number of scheduled Breathlessness Visual Analogue Scale assessments, multiplied by 100. The Breathlessness Visual Analogue Scale assesses breathlessness severity during the past week on a scale from 0 to 100, with higher scores indicating greater breathlessness severity.

Up to 52 weeks
Percentage of Scheduled Patient-Reported Measures Completed
時間枠:Baseline, 3 months, 6 months, 9 months and 12 months

Completion of scheduled patient-reported measures will be assessed across the Idiopathic Pulmonary Fibrosis Patient Reported Outcome Measure (IPF-PROM), Idiopathic Pulmonary Fibrosis Patient Reported Experience Measure (IPF-PREM), EQ-5D-5L, SpiroQ Home Spirometry Satisfaction Questionnaire, Patient Health Questionnaire-9 (PHQ-9), Generalised Anxiety Disorder-7 (GAD-7), and Porter-Novelli 10-item Patient Engagement Scale. The outcome will be calculated as the number of scheduled patient-reported measures completed divided by the total number of patient-reported measures scheduled for completion, multiplied by 100, and reported as a percentage.

Baseline, 3 months, 6 months, 9 months and 12 months
Percentage of Clinician-Confirmed Clinical Deterioration Events Without a Preceding AIRM Alert
時間枠:Up to 52 weeks

Calculated as the number of clinician-confirmed clinical deterioration events occurring without a preceding AIRM alert within the previous 4 weeks divided by the total number of clinician-confirmed clinical deterioration events, multiplied by 100. The outcome will be reported as a percentage.

Up to 52 weeks
Number of Device-Related Adverse Events
時間枠:Up to 52 weeks

Number of adverse events related to the remote monitoring devices or monitoring platform during the 12-month active remote monitoring period.

Up to 52 weeks
Percentage of Participants Reporting Remote Monitoring as Easy or Very Easy
時間枠:Baseline, 3 months, 6 months, 9 months and 12 months

Participant acceptability will be assessed using the SpiroQ Satisfaction Questionnaire. Participants rate the ease of remote monitoring using response categories ranging from "very easy" to "very difficult", with an additional "I don't know/not applicable" option. The outcome will be reported as the percentage of participants selecting "easy" or "very easy."

Baseline, 3 months, 6 months, 9 months and 12 months
Clinician Perspectives on the Acceptability of AIRM
時間枠:Up to 15 months

Clinician acceptability will be explored through focus groups with clinicians involved in the AIRM remote monitoring pathway. Qualitative data will be analysed thematically to identify themes relating to the acceptability of using AIRM within clinical practice.

Up to 15 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Percentage of AIRM Alerts That Are False-Positive Alerts
時間枠:Up to 52 weeks

Calculated as the number of AIRM alerts not associated with a clinician-confirmed clinical deterioration event divided by the total number of AIRM alerts, multiplied by 100.

Up to 52 weeks
Sensitivity of AIRM for Identifying Clinically Significant Deterioration Events
時間枠:Up to 52 weeks

Calculated as the number of clinician-confirmed clinical deterioration events identified by AIRM divided by the total number of clinician-confirmed clinical deterioration events, multiplied by 100.

Up to 52 weeks
Percentage of AIRM Alerts Leading to Clinical Review
時間枠:Up to 52 weeks

Calculated as the number of AIRM-generated alerts that result in clinical review by a clinician divided by the total number of AIRM-generated alerts, multiplied by 100. The outcome will be reported as a percentage.

Up to 52 weeks
Percentage of AIRM Alerts Leading to Clinical Intervention
時間枠:Up to 52 weeks

Calculated as the number of AIRM-generated alerts that result in clinical intervention divided by the total number of AIRM-generated alerts, multiplied by 100. The outcome will be reported as a percentage.

Up to 52 weeks
Number of Emergency Hospital Admissions
時間枠:Up to 12 months

The total number of emergency hospital admissions occurring during the 12-month study period will be recorded for each participant and summarised across the study population.

Up to 12 months
Number of Outpatient Attendances
時間枠:Up to 12 months

The total number of outpatient attendances occurring during the 12-month study period will be recorded for each participant and summarised across the study population.

Up to 12 months
Number of Other Clinically Relevant Healthcare Contacts
時間枠:Up to 12 months

The total number of other clinically relevant healthcare contacts, e.g. helpline, occurring during the 12-month study period will be recorded for each participant and summarised across the study population.

Up to 12 months

その他の成果指標

結果測定
メジャーの説明
時間枠
Specificity of AIRM for Identifying Clinically Significant Deterioration Events
時間枠:Up to 52 weeks

The specificity of AIRM for identifying clinically significant deterioration will be assessed by comparing AIRM predictions with clinician-confirmed clinical deterioration. Specificity will be calculated as the proportion of events without clinically significant deterioration that are correctly identified by AIRM as not indicating deterioration and will be reported as a percentage.

Up to 52 weeks
Area Under the Receiver Operating Characteristic Curve (AUROC) for Artificial Intelligence enhanced Remote Monitoring Prediction of Clinical Deterioration
時間枠:Up to 52 weeks

The discriminative performance of Artificial Intelligence enhanced Remote Monitoring for predicting clinician-confirmed clinical deterioration will be assessed using the area under the receiver operating characteristic curve (AUROC). AUROC values range from 0.5 to 1.0, with higher values indicating greater ability to discriminate between deterioration and non-deterioration.

Up to 52 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年12月1日

一次修了 (推定)

2028年3月1日

研究の完了 (推定)

2028年6月1日

試験登録日

最初に提出

2026年9月16日

QC基準を満たした最初の提出物

2026年9月21日

最初の投稿 (実際)

2026年9月28日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月28日

QC基準を満たした最後の更新が送信されました

2026年9月21日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • 353066

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する